This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Skeletal Targeted Radiotherapy

Poniard Pharmaceuticals, Inc.

Drug Names(s): STR, 166Ho-DOTMP

Description: Skeletal targeted radiotherapy (STR) is composed of the radionuclide holmium-166 complexed to abone-targeting molecule, DOTMP. When injected into a patient's bloodstream, STR rapidly binds to bone mineral, delivering a brief, intense dose of radiation to destroy cancer cells in the bone marrow, the major disease site in multiple myeloma. STR treatment is followed by infusion of the patient’s own previously collected blood stem cells to restore bone marrow function.

Deal Structure: Poniard and ALLOZYNE
In June 2011, Poniard Pharmaceuticals announced the signing of a definitive merger agreement with ALLOZYNE. If the merger is consummated, the combined company will be renamed ALLOZYNE, Inc. and will be based in Seattle. The merger was terminated in December 2011.

Skeletal Targeted Radiotherapy News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug